ABBV Pharmaceutical Preparations / ABBV, NYSE

AbbVie Inc. revenue $16.99B, quarter ended Jun 30, 2026

AbbVie Inc. reported $16.99B of revenue in the quarter ended Jun 30, 2026, +10.2% on the quarter ended Jun 30, 2025. Across the six months ended Jun 30, 2026, $31.99B, +11.2% on the six months ended Jun 30, 2025.

Quarterly revenue, quarter ended Jun 30, 2026 $16.99B

+10.2% year over year +$1.57B against $15.42B for the quarter ended Jun 30, 2025

Six months ended Jun 30, 2026 $31.99B +11.2% JMM's sum of the 2 contiguous quarters below, 181 days end to end, each one accession-linked. Measured against the $28.77B of the six months ended Jun 30, 2025.

Every ABBV quarter JMM stores, on a real time axis

Open SEC company facts

Quarterly revenue, 8 stored SEC reporting periods, US dollars. Bars sit on a real time axis and are as wide as the period they report, so a quarter the stored set does not hold reads as a gap rather than as a step. The lower band is empty for a period whose year-ago quarter is not in the stored set.

Which quarters built the six months ended Jun 30, 2026, and which carried the change

Six months ended Jun 30, 2026 $32.0B +$3.2B

$15.0B quarter ended Mar 31 $17.0B quarter ended Jun 30

Six months ended Jun 30, 2025 $28.8B

$13.3B quarter ended Mar 31 $15.4B quarter ended Jun 30

Quarter ended Mar 31, 2026 $15.0B against $13.3B for the quarter ended Mar 31, 2025 +$1.7B 51% of the change 10-Q
Quarter ended Jun 30, 2026 $17.0B against $15.4B for the quarter ended Jun 30, 2025 +$1.6B 49% of the change 10-Q

Quarterly revenue for each quarter in the window, in US dollars, both bars drawn to one scale so the difference in length is the change. Every value is the figure tagged in the filing the row links to; the totals are JMM's sum of those quarters and the change is measured against the same 2 quarters one year earlier, not against the window before this one.

What the ABBV record says, and what to quote from it

Growth is slowing, from +12.4% for the quarter ended Mar 31, 2026 to +10.2%.

The last 5 comparable prints run +8.4%, +6.6%, +9.1%, +12.4%, +10.2%, so the latest rate is 2.3 points below the quarter before it, and the fastest quarter in this run was +12.4% for the period ended Mar 31, 2026. Here is what those points are worth: at +12.4%, the quarter ended Jun 30, 2026 would have printed $17.34B instead of $16.99B. The $350.62M between them is the whole of what decelerating means at this size.

The sequential step, +13.3% from the quarter ended Mar 31, 2026, is mostly this issuer's own seasonality, which is why it is not the headline here and not the headline anywhere serious.

These quarters do not close a fiscal year. SEC builds its quarterly frames from the values a filer tags, and most filers tag no standalone fourth quarter: it is reported inside the annual filing as part of the year. Six months ended Jun 30, 2026 is the largest total they genuinely close, and it is the second figure above. The annual report in ABBV's filing history carries the year as AbbVie Inc. reports it.

ABBV quarterly revenue, filing by filing

All ABBV filings

Period ended	Quarterly revenue	Year over year	Filed	Evidence
Jun 30, 202610-Q	$17.0B	+10.2% vs $15.4B, period ended Jun 30, 2025	Aug 3, 2026	Open filing
Mar 31, 202610-Q	$15.0B	+12.4% vs $13.3B, period ended Mar 31, 2025	May 8, 2026	Open filing
Sep 30, 202510-Q	$15.8B	+9.1% vs $14.5B, period ended Sep 30, 2024	Nov 4, 2025	Open filing
Jun 30, 202510-Q	$15.4B	+6.6% vs $14.5B, period ended Jun 30, 2024	Aug 3, 2026	Open filing
Mar 31, 202510-Q	$13.3B	+8.4% vs $12.3B, period ended Mar 31, 2024	May 8, 2026	Open filing
Sep 30, 202410-Q	$14.5B	Not stored no quarter one year earlier in the stored set	Nov 4, 2025	Open filing
Jun 30, 202410-Q	$14.5B	Not stored no quarter one year earlier in the stored set	Aug 4, 2025	Open filing
Mar 31, 202410-Q	$12.3B	Not stored no quarter one year earlier in the stored set	May 9, 2025	Open filing

Period endedJun 30, 202610-Q, filed Aug 3, 2026 Quarterly revenue$17.0B Year over year +10.2% vs $15.4B, period ended Jun 30, 2025 Open filing Period endedMar 31, 202610-Q, filed May 8, 2026 Quarterly revenue$15.0B Year over year +12.4% vs $13.3B, period ended Mar 31, 2025 Open filing Period endedSep 30, 202510-Q, filed Nov 4, 2025 Quarterly revenue$15.8B Year over year +9.1% vs $14.5B, period ended Sep 30, 2024 Open filing Period endedJun 30, 202510-Q, filed Aug 3, 2026 Quarterly revenue$15.4B Year over year +6.6% vs $14.5B, period ended Jun 30, 2024 Open filing Period endedMar 31, 202510-Q, filed May 8, 2026 Quarterly revenue$13.3B Year over year +8.4% vs $12.3B, period ended Mar 31, 2024 Open filing Period endedSep 30, 202410-Q, filed Nov 4, 2025 Quarterly revenue$14.5B Year over year Not stored no quarter one year earlier in the stored set Open filing Period endedJun 30, 202410-Q, filed Aug 4, 2025 Quarterly revenue$14.5B Year over year Not stored no quarter one year earlier in the stored set Open filing Period endedMar 31, 202410-Q, filed May 9, 2025 Quarterly revenue$12.3B Year over year Not stored no quarter one year earlier in the stored set Open filing

Every row is the SEC concept Revenues, read from the SEC company facts API by the JMM collector, checked Aug 7, 2026. The change column is year over year and names the exact period it was measured against, because these periods are not contiguous: a change against whichever row happens to sit below would compare quarters up to three years apart. Earlier rows carry the accession SEC attributes the value to, which can be a later filing that restated the period, so only the most recent row's 34-day gap is a reporting delay.

ABBV against every other Pharmaceutical Preparations filer JMM covers

Open the full company index

Each issuer's latest stored quarter, in USD, for every filer JMM covers under SEC SIC 2834. Fiscal calendars differ, so these periods end on different dates: the bars compare scale, not a shared quarter. Coverage is JMM's, not the classification's, so this is not the whole industry.

Continue from the AbbVie Inc. record

GuideAudit a quarterly revenue figure in SEC company facts

Reproduce any row in the table below from the raw XBRL frames, period by period.

CalculatorAnnualize the growth between any two of these quarters

Paste a starting and ending value from the table to get a compound annual rate, before and after CPI-U inflation.

GuideWhat the XBRL tag behind this figure actually measures

Why two issuers reporting the same business can carry different revenue concepts, and what that changes about comparing them.